第12批国家组织药品集采开标 强化反内卷规则与基层供应保障

第12批国家组织药品集采于7月31日在上海开标 1。本次集采共有65种药品采购成功，327家企业的521个产品获得拟中选资格 1。

此轮集采延续了前期集采的成本控制成果。与2019年相比，集采仿制药每年可节约医保经费约1600亿元 1。药品耗材集采累计节约基金约4400亿元，其中超八成结余资金被用于支持创新药进入医保目录 1。具体来看，降糖药价格已从原来每瓶120元降至8.9元，心脏冠脉支架单价从17000元降至850元 1。前九批集采的1600余个中选产品中，国产仿制药中标占比达96%，原研药中标比例仅为4%左右 1。

与以往相比，本批集采强化了反内卷规则、质量监管要求和基层供应保障 1。医院理论上仍保留30%的采购份额可从未中选产品中自行采购 1。同时，上海推行医保定额报销政策，自5月起社区医院可按需自主配备原研药等非中选药品，患者因此可按需选择，医保则按集采中选价格作为支付标准 1。

China's 12th batch of centralized drug procurement opened for bidding on July 31 in Shanghai, with 65 drugs successfully procured and 521 products from 327 enterprises receiving preliminary selection qualification 1. The new procurement round introduces strengthened rules against price-cutting competition, enhanced quality oversight requirements, and improved supply assurance for grassroots healthcare facilities 1.

The centralized procurement program continues to demonstrate significant cost savings for the healthcare system. Compared to 2019, annual medical insurance savings from generic drug procurement have reached approximately 1.6 billion yuan 1. Across all procurement rounds, the cumulative savings exceed 4.4 billion yuan, with over 80 percent of surplus funds allocated to support innovative drugs entering medical insurance coverage 1. Notable price reductions include diabetes medications that dropped from 120 yuan per bottle to 8.9 yuan, and coronary stents that fell from 17,000 yuan to 850 yuan per unit following procurement 1. Among products selected in the first nine procurement rounds, domestic generic drugs account for 96 percent of winning bids, while original brand-name drugs represent only approximately 4 percent 1.

Shanghai has implemented a new medical insurance fixed-rate reimbursement policy allowing community hospitals to independently procure non-selected original brand-name drugs since May this year, with medical insurance payments calculated based on the centralized procurement price 1. Hospitals theoretically retain 30 percent purchasing discretion to source non-selected products independently 1.